Professor Michiel Rienstra and Dr Bao-Oanh Nguyen (University Medical Center Groningen, Groningen, The Netherlands) gave us an overview of the RACE-3 study (NCT00877643) from the European Heart Rhythm Association (EHRA) Virtual Meeting 2021.
Questions:
- What is the rationale for targeted therapy of underlying conditions in patients with persistent atrial fibrillation (AF) and mild to moderate stable heart failure (HF)? (0.31)
- Could you tell us a little about the RACE-3 study and its findings? (1.50)
- Among the interventions investigated in the study, which appeared to be most and least effective? (3.58)
- What follow-up studies are planned? (4.58)
- Following the results of this study, how do you envision the standard of care developing for patients with AF, with and without HF? (5.35)
Speaker disclosures: Prof. Michiel Rienstra wishes to disclose that RACE 3 was supported by the Netherlands Heart Foundation (Grant 2008B035), and the Netherlands Heart Institute. Further, this trial was funded by unrestricted grants from AstraZeneca, Bayer, Biotronik, Boehringer-Ingelheim, Boston Scientific, Medtronic, Sanofi-Aventis and St-Jude-Medical, paid to the Netherlands Heart Institute. Dr Bao-Oanh Nguyen has nothing to declare in relation to this video interview.
Interview and filming supported by Touch Medical Media. Interview conducted by Heather Hall.
Filmed during a remote video call with Prof. Michiel Rienstra and Dr Bao-Oanh Nguyen as a highlight of EHRA 2021, May 2021
